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The primary objective of phase II trials is to screen a new agent or regimen for efficacy and to provide estimates of its level of activity. In this workshop we will discuss commonly used endpoints such as complete plus partial response rate (overall response rate) and their corresponding analysis and interpretation. The use of multiple-stage design to minimize increase the efficiency of screening will be discussed. The importance in the design of phase II trials to minimize the chance that a truly active agent is erroneously rejected will also be discussed. There are circumstances that randomized phase II trial may be appropriate and its correct interpretation will be discussed. With the advancement in the understanding of multiple signaling pathways associated with lung cancer, many targeted therapies have been developed. Utilization of molecularly targeted agents can inhibit these specific aberrant pathways, hence, lead to clinical efficacy. The targeted agents, however, may not work for everyone. Biomarkers expressions can be used as indicators for the aberrant signaling to identify effective targeted therapy. Our major goals are to characterize the molecular signature of individual tumors, to offer bestfit targeted therapy to patients on the trial, and to identify promising targeted agents for future development. Methods: We have developed the "BATTLE" program, "Biomarkerintegrated Approaches of Targeted Therapy of Lung Cancer Elimination," which consists of an umbrella screening trial and 4 parallel phase II targeted therapies trials (with erlotinib, sorafenib, vandetanib, and the combination of erlotinib and bexarotene) in advanced non-small cell lung cancer patients with prior chemotherapy. All patients will have biopsy samples taken for biomarker profile assessment prior to the randomization, then they will be classified into one of the five marker groups: 1) EGFR mutation/amplification, 2) K-ras and/or B-raf mutation, 3) VEGF and/or VEGFR expression, 4) RXR and/or cyclin
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